Sinuva is a drug owned by Intersect Ent Inc. It is protected by 13 US drug patents filed from 2018 to 2019. Out of these, 7 drug patents are active and 6 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 24, 2034. Details of Sinuva's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10232152 | Systems, devices, and method for treating a sinus condition |
Nov, 2034
(9 years from now) | Active |
| US10406332 | Systems, devices, and method for treating a sinus condition |
Mar, 2034
(9 years from now) | Active |
| US8763222 | Methods and devices for crimping self-expanding devices |
Feb, 2032
(7 years from now) | Active |
| US10357640 | Expandable devices and methods for treating a nasal or sinus condition |
Oct, 2031
(6 years from now) | Active |
| US8025635 | Device and methods for treating paranasal sinus conditions |
Jun, 2027
(2 years from now) | Active |
| US7544192 | Sinus delivery of sustained release therapeutics |
Nov, 2026
(1 year, 11 months from now) | Active |
| US9585681 | Device and methods for treating paranasal sinus conditions |
Apr, 2026
(1 year, 3 months from now) | Active |
| US7951130 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
| US7713255 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
| US7662141 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
| US7951133 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
| US7951131 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
| US8109918 | Sinus delivery of sustained release therapeutics |
Mar, 2024
(9 months ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sinuva's patents.
Latest Legal Activities on Sinuva's Patents
Given below is the list of recent legal activities going on the following patents of Sinuva.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 12 Apr, 2024 | US8109918 |
| Mail O.P. Petition Decision | 12 Apr, 2024 | US8109918 |
| Mail-Record Petition Decision of Granted to Make Entity Status large | 09 Apr, 2024 | US8109918 |
| O.P. Petition Decision | 08 Apr, 2024 | US8109918 |
| Record Petition Decision of Granted to Make Entity Status large | 08 Apr, 2024 | US8109918 |
| Payment of Maintenance Fee under 1.28(c) | 13 Feb, 2024 | US8109918 |
| Petition Entered | 13 Feb, 2024 | US8109918 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 13 Feb, 2024 | US8109918 |
| Change in Power of Attorney (May Include Associate POA) Critical | 09 Feb, 2024 | US8109918 |
| Email Notification Critical | 09 Feb, 2024 | US8109918 |
FDA has granted several exclusivities to Sinuva. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Sinuva, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Sinuva.
Exclusivity Information
Sinuva holds 1 exclusivities. All of its exclusivities have expired in 2020. Details of Sinuva's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 08, 2020 |
US patents provide insights into the exclusivity only within the United States, but Sinuva is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sinuva's family patents as well as insights into ongoing legal events on those patents.
Sinuva's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sinuva's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Nov 24, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sinuva Generic API suppliers:
Mometasone Furoate is the generic name for the brand Sinuva. 14 different companies have already filed for the generic of Sinuva, with Cosette having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Sinuva's generic
Alternative Brands for Sinuva
Sinuva which is used for treating nasal polyps in adult patients who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant., has several other brand drugs using the same active ingredient (Mometasone Furoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||
|---|---|---|---|---|---|
| Glenmark Speclt |
| ||||
| Organon Llc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Mometasone Furoate, Sinuva's active ingredient. Check the complete list of approved generic manufacturers for Sinuva
About Sinuva
Sinuva is a drug owned by Intersect Ent Inc. It is used for treating nasal polyps in adult patients who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant. Sinuva uses Mometasone Furoate as an active ingredient. Sinuva was launched by Intersect Ent Inc in 2017.
Approval Date:
Sinuva was approved by FDA for market use on 08 December, 2017.
Active Ingredient:
Sinuva uses Mometasone Furoate as the active ingredient. Check out other Drugs and Companies using Mometasone Furoate ingredient
Treatment:
Sinuva is used for treating nasal polyps in adult patients who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant.
Dosage:
Sinuva is available in implant form for implantation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.35MG | IMPLANT | Prescription | IMPLANTATION |